Notably, a combination therapy involving anti-EDB-IL-2 (L19-IL2) and anti-EDB-TNF (L19-TNF) has advanced to phase III trials to explore the efficacy of intratumoral treatment followed by surgery in clinical stage IIIB/C melanoma patients (NCT03567889 and NCT02938299). This evidence concerns the gene IL2 and melanoma.